Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
NRSN NeuroSense Therapeutics
1.690+0.030+1.81%
Close
01/27 16:00 ET
1.570-0.120-7.10%
Post Mkt Price 01/27 17:55 ET
High
1.740
Open
1.660
Turnover
176.40K
Low
1.550
Pre Close
1.660
Volume
108.74K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Gainers Jeffs' Brands Ltd (NASDAQ:JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday.Pliant Therapeutics, Inc. (NASDAQ:PLRX) rose 48.8% to $33.49 in pre-market trading after
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ:HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets.Genius Group Limited (NYSE:GNS) shares jumped 96
Maxim Group Sticks to Its Buy Rating for Neurosense Therapeutics Ltd. (NRSN)
Cosmos, InMed Top Healthcare Gainers; Innovative, Panbela Lead Losers' Pack
Nordstrom, Bed Bath & Beyond, Synlogic Among Premarket Losers' Pack
Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Gainers Genius Group Limited (NYSE:GNS) rose 52.2% to $3.18 in pre-market trading. Genius Group shares jumped 290% on Thursday after the company approved a plan to create an 'Illegal Trading Task For
Top Premarket Decliners
07:49 AM EST, 01/20/2023 (MT Newswires) -- AcelRx (ACRX) shares declined 20%, adding to Thursday's losses. Panbela Therapeutics (PBLA) shares dropped 20% following a 2.4% loss in the previous session.
NeuroSense Therapeutics Files For Mixed-Securities Shelf Offering Of Up To $100M
NeuroSense Therapeutics Files For Mixed-Securities Shelf Offering Of Up To $100M
NeuroSense Files $100M Mixed Securities Shelf
Top Midday Gainers
01:47 PM EST, 01/19/2023 (MT Newswires) -- Genius Group (GNS) said its board approved an action plan to address alleged "illegal short-selling" of its stock. The plan includes creating a board-led tas
Company Overview
More
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
CEO： Mr. Alon Ben-Noon
Market： NASDAQ
Listing Date： 12/09/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet